Sage Therapeutics (SAGE) shares have surged in early trading today after the company announced successful results in a Phase 2 clinical trial assessing lead product candidate SAGE-547 for the treatment of severe postpartum depression (PPD). The study met its primary endpoint of a statistically valid reduction in depression symptoms from baseline compared to placebo as measured by the total score in the Hamilton Rating Scale for Depression (HAM-D) at 60 hours (p=0.008). Additionally, the statistically significant difference in treatment effect began at hour 24 (p=0.006) and remained in effect at similar magnitude through the 30-day follow-up period (p=0.01).